TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer

Akiko Arimura,Kazuko Sakai,Kazuhisa Kaneshiro,Takafumi Morisaki,Saori Hayashi,Kimihisa Mizoguchi,Mai Yamada,Masaya Kai,Mayumi Ono,Kazuto Nishio,Masafumi Nakamura,Makoto Kubo
DOI: https://doi.org/10.3390/cancers16061184
2024-03-18
Cancers
Abstract:Precise biomarkers for predicting the therapeutic efficacy of molecularly targeted drugs are limited at the protein level; thus, it has been important to broadly scrutinize individual cancer driver gene mutations for effective cancer treatments. Multiplex cancer genome profiling can comprehensively identify gene mutations that are therapeutic targets using next-generation sequencing (NGS). In addition, circulating tumor DNA (ctDNA) is a DNA fragment released into the blood by tumor cell-derived cell death or apoptosis. Liquid biopsy with ctDNA is a novel clinical test for identifying genetic mutations in an entire population noninvasively, in real-time, and heterogeneously. Although there are several reports on ctDNA, fewer have evaluated ctDNA with NGS before an initial treatment for breast cancer patients. Therefore, we examined whether analyzing tumor-associated gene mutations in primary breast cancer based on ctDNA could serve as a biomarker for prognosis and optimal treatment selection. Ninety-five primary breast cancer patients treated at our department from January 2017 to October 2020 were included. Pretreatment plasma samples were subjected to NGS analysis of ctDNA, and correlations with patients' clinicopathological characteristics were evaluated. Fifty-nine (62.1%) patients were positive for ctDNA. ctDNA tended to be positive in hormone receptor-negative, and TP53 (34%), BRCA1 (20%), and BRCA2 (17%) gene mutations were more frequent. Regarding recurrence-free survival, the prognosis was poor in the TP53 and/or BRCA1 mutation-positive groups, especially in triple-negative breast cancer (TNBC) patients. In conclusion, the results of this study indicate that ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients and for those for whom optimal treatment selection is desirable; additionally, optimal treatment could be selected according to the ctDNA analysis results.
oncology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to identify prognostic biomarkers in triple - negative breast cancer (TNBC) patients through circulating tumor DNA (ctDNA) analysis, with the aim of identifying patient groups with poor prognosis before treatment and selecting the best treatment options for these patients. Specifically, the researchers focused on the detection of TP53 and BRCA1 gene mutations in ctDNA and evaluated their effectiveness as potential biomarkers for the prognosis of TNBC patients. ### Research Background and Objectives - **Background**: Triple - negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), accounting for approximately 20% of all breast cancers. Due to the lack of effective targeted treatment methods, TNBC is usually highly invasive and has a poor prognosis. - **Objectives**: By analyzing TP53 and BRCA1 gene mutations in ctDNA, evaluate whether these mutations can be used as prognostic biomarkers for TNBC patients and help doctors identify high - risk patients before treatment, thereby optimizing treatment strategies. ### Main Findings - **ctDNA Positive Rate**: Among 95 patients with primary breast cancer, 59 (62.1%) patients had positive ctDNA test results. - **Mutation Frequency**: The most common mutated gene was TP53 (34%), followed by BRCA1 (20%) and BRCA2 (17%). - **Prognosis Analysis**: Kaplan - Meier survival analysis showed that the recurrence - free survival rate (RFS) of TNBC patients with positive TP53 or BRCA1 mutations was significantly lower than that of mutation - negative patients (p = 0.0054 and p = 0.0030). In particular, in the TNBC subgroup, TP53 or BRCA1 mutations were significantly associated with a poorer prognosis (p = 0.0107 and p = 0.0150). ### Conclusions - **Main Conclusions**: TP53 and BRCA1 mutations in ctDNA can be used as prognostic biomarkers for TNBC patients, which helps to identify patients with poor prognosis before treatment and thus guide the selection of personalized treatment plans. ### Significance - **Clinical Application**: Through ctDNA analysis, key gene mutations can be detected quickly and accurately in a non - invasive manner, providing more accurate prognosis evaluation and treatment recommendations for TNBC patients. - **Future Directions**: Further research can explore the role of more gene mutations in ctDNA and how to integrate these biomarkers into clinical practice to improve the treatment effect and survival rate of TNBC patients. Hope this information is helpful to you! If you have any other questions or need further explanation, please feel free to let me know.